Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus
Authors' conclusion
AdoSLE on High-IS induced lower SARS-CoV-2 vaccine immune responses than Low-IS.
Study context
- Population
- Patients aged 12–18 years diagnosed with SLE receiving two doses of BNT162b2 4 weeks apart and a booster at 4–6 months
- Participants
- 73 patients
- Exposure
- High-dose vs low-dose immunosuppressant in adolescents with SLE receiving BNT162b2
- High-ISn = 40
- Low-ISn = 33reference
- Outcome
- Anti-RBD IgG seropositivity (overall)
- Follow-up
- 4 weeks after 2nd dose
Main finding
As reported in the abstract
Overall anti-RBD IgG seropositivity
97.3%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Anti-RBD IgG, Wuhan NT and IFN-γ-ELISpot · 4 weeks after 2nd doseHigh-IS vs Low-IS | P < 0.001 |
| Anti-RBD IgG, Wuhan NT and IFN-γ-ELISpot · 4 weeks after 2nd doseHigh-IS vs Low-IS | P < 0.001 |
| Anti-RBD IgG, Wuhan NT and IFN-γ-ELISpot · 4 weeks after 2nd doseHigh-IS vs Low-IS | P = 0.022 |
Antibody response after 3rd dose vs after 2nd dose
- Significantly higher antibody responses after 3rd dose in both groups, with seroconversion against Omicron; persistently lower antibody levels in High-IS
- P < 0.001
Safety
SELENA-SLEDAI score within 12 weeks after 2-dose vaccination vs before
- After vs before vaccination
- 3.1 vs 2.5; p < .036
- Disease flare by SELENA-SLEDAI flare index not different after vs before vaccination, consistent across groups
Non-severe adverse events (AEs)
- Occurred similarly in both groups
Original publication
Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus. Lupus. Published 9 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →